Pfizer begins late-stage trial for new pneumococcal shot in infants after strong Phase 2 data
Pfizer Inc. · PHARMACEUTICAL PREPARATIONS · Now $26.18
+0.6% in 1d after detection
Post-detection moves
1h
—
1d
+0.6%
3d
+0.2%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS